|
A. Grant Heidrich, III has served as a member of our board of directors since April 1998. Mr. Heidrich has been in venture capital for 25 years, principally at Mayfield where he is currently a Partner Emeritus. For more than two decades he was a Managing Director in Mayfield Funds IV-X. During his tenure at Mayfield, he co-managed Mayfield's healthcare investing activities. He currently serves on the boards of Millennium Pharmaceuticals (MLNM), Aveo Pharmaceuticals and other private companies. Mr. Heidrich also served as Chairman of the Board of Tularik (TLRK) until it was acquired by Amgen (AMGN). He is also Chairman of the Advisory Board of Harvard Partners Center for Genetics and Genomics. Mr. Heidrich was the past President of the Western Association of Venture Capital and former member of the Board of Directors of the National Venture Capital Association. During his venture career, he has been on the Boards of more than 20 public and private companies. He received a BA from Stanford University in the Department of Human Biology, and an MBA from Columbia University. | 